Latest Breaking News On - Michiel hemels - Page 1 : comparemela.com

Philippe Motté as Senior VP, Regulatory and QualityMichiel Hemels as VP, Global Pricing and Market AccessPARIS (BUSINESS WIRE) Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for reti.

France generalUnited statesClothilde cailletJames palmerGensight biologics euronextMichiel hemelsGuillaume van renterghemJeanene timberlakeGensight biologicsPhilippe mottBernard gillySissel rodahlPostdoctoral fellowship at harvard medical schoolFrench national academy of pharmacyUniversity of utrechtHospital cancer center